Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.31 |
| ▸ | TUBB | P07437 | 2/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22186154 | 0.81 | ACHE (0.43) | CYP2A6ERN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7481017 | 0.79 | CYP2A6 (0.52) | CYP2A6 | |
| SCHEMBL10731147 | 0.79 | CYP2A6 (0.37) | CYP2A6PDE3BPDE3A | |
| SCHEMBL7470456 | 0.77 | CYP2A6 (0.50) | CYP2A6ALDH1A1 | |
| SCHEMBL4264988 | 0.74 | CYP2A6 (0.47) | CYP2A6 | |
| SCHEMBL3483704 | 0.71 | CYP2A6 (0.37) | CYP2A6ALDH1A1IDO1 | |
| SCHEMBL22132791 | 0.71 | ERN1 (0.34) | MAP3K14ERN1ALDH1A1TRPV4L3MBTL1 | |
| SCHEMBL787838 | 0.70 | NQO2 (0.40) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL24227136 | 0.67 | GAA (0.32) | MAP3K14ERN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22132832 | 0.67 | ERN1 (0.37) | MAP3K14ERN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3670513-B1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | CSPC ZHONGQI PHARMACEUTICALL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20200207773-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| EP-3670513-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2020-06-24 | — | — | EP | disclosed |
| EP-2134683-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | FGFR1, FGFR2, FGFR4 | CYP2A6 2645/4885MAP3K14 510/4885ERN1 3460/4885 |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | CYP2A6 1364/4885MAP3K14 1543/4885ERN1 69/4885 |
| US-20200207773-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | FGFR1, FGFR2, FGFR3 | CYP2A6 2860/4885MAP3K14 295/4885ERN1 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.